175 related articles for article (PubMed ID: 17889485)
1. In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea.
Ruiz J; Mensa L; O'Callaghan C; Pons MJ; González A; Vila J; Gascón J
Diagn Microbiol Infect Dis; 2007 Dec; 59(4):473-5. PubMed ID: 17889485
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea.
Sierra JM; Ruiz J; Navia MM; Vargas M; Vila J
Antimicrob Agents Chemother; 2001 Feb; 45(2):643--4. PubMed ID: 11269233
[No Abstract] [Full Text] [Related]
3. In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler's diarrhea and Clostridium difficile.
Farrell DJ; Putnam SD; Biedenbach DJ; Moro L; Bozzella R; Celasco G; Jones RN
Antimicrob Agents Chemother; 2011 Mar; 55(3):992-6. PubMed ID: 21149623
[TBL] [Abstract][Full Text] [Related]
4. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions.
Gomi H; Jiang ZD; Adachi JA; Ashley D; Lowe B; Verenkar MP; Steffen R; DuPont HL
Antimicrob Agents Chemother; 2001 Jan; 45(1):212-6. PubMed ID: 11120968
[TBL] [Abstract][Full Text] [Related]
5. In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008.
Ouyang-Latimer J; Jafri S; VanTassel A; Jiang ZD; Gurleen K; Rodriguez S; Nandy RK; Ramamurthy T; Chatterjee S; McKenzie R; Steffen R; DuPont HL
Antimicrob Agents Chemother; 2011 Feb; 55(2):874-8. PubMed ID: 21115800
[TBL] [Abstract][Full Text] [Related]
6. Rifaximin--a novel antimicrobial for enteric infections.
Huang DB; DuPont HL
J Infect; 2005 Feb; 50(2):97-106. PubMed ID: 15667909
[TBL] [Abstract][Full Text] [Related]
7. Rifaximin--the promising anti-microbial for enteric infections.
Arya SC; Agarwal N
J Infect; 2005 Oct; 51(3):262. PubMed ID: 16125780
[No Abstract] [Full Text] [Related]
8. Bile acids improve the antimicrobial effect of rifaximin.
Darkoh C; Lichtenberger LM; Ajami N; Dial EJ; Jiang ZD; DuPont HL
Antimicrob Agents Chemother; 2010 Sep; 54(9):3618-24. PubMed ID: 20547807
[TBL] [Abstract][Full Text] [Related]
9. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders.
Adachi JA; DuPont HL
Clin Infect Dis; 2006 Feb; 42(4):541-7. PubMed ID: 16421799
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity and fecal concentration of rifaximin after oral administration.
Jiang ZD; Ke S; Palazzini E; Riopel L; Dupont H
Antimicrob Agents Chemother; 2000 Aug; 44(8):2205-6. PubMed ID: 10898704
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of rifaximin against bacterial enteropathogens causing diarrhoea in children under 5 years of age in Ifakara, Tanzania.
Sierra JM; Navia MM; Vargas M; Urassa H; Schellemberg D; Gascón J; Vila J; Ruiz J
J Antimicrob Chemother; 2001 Jun; 47(6):904-5. PubMed ID: 11389133
[No Abstract] [Full Text] [Related]
12. Antibacterial chemoprophylaxis in the prevention of traveler's diarrhea: evaluation of poorly absorbed oral rifaximin.
DuPont HL; Jiang ZD; Okhuysen PC; Ericsson CD; de la Cabada FJ; Ke S; DuPont MW; Martinez-Sandoval F
Clin Infect Dis; 2005 Dec; 41 Suppl 8():S571-6. PubMed ID: 16267721
[TBL] [Abstract][Full Text] [Related]
13. Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability.
Ruiz J; Mensa L; Pons MJ; Vila J; Gascon J
J Antimicrob Chemother; 2008 May; 61(5):1016-9. PubMed ID: 18325895
[TBL] [Abstract][Full Text] [Related]
14. Relevant role of efflux pumps in high levels of rifaximin resistance in Escherichia coli clinical isolates.
Gomes C; Ruiz L; Pons MJ; Ochoa TJ; Ruiz J
Trans R Soc Trop Med Hyg; 2013 Sep; 107(9):545-9. PubMed ID: 23843564
[TBL] [Abstract][Full Text] [Related]
15. Traveler's diarrhea.
Yates J
Am Fam Physician; 2005 Jun; 71(11):2095-100. PubMed ID: 15952437
[TBL] [Abstract][Full Text] [Related]
16. Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei.
Jiang ZD; Ke S; Dupont HL
Int J Antimicrob Agents; 2010 Mar; 35(3):278-81. PubMed ID: 20045287
[TBL] [Abstract][Full Text] [Related]
17. Rifamycin SV MMX for the treatment of traveler's diarrhea.
Lin SW; Lin CJ; Yang JC
Expert Opin Pharmacother; 2017 Aug; 18(12):1269-1277. PubMed ID: 28697313
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial resistance of Shigella isolates causing traveler's diarrhea.
Vila J; Gascon J; Abdalla S; Gomez J; Marco F; Moreno A; Corachan M; Jimenez de Anta T
Antimicrob Agents Chemother; 1994 Nov; 38(11):2668-70. PubMed ID: 7872767
[TBL] [Abstract][Full Text] [Related]
19. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci.
DuPont HL; Jiang ZD
Clin Microbiol Infect; 2004 Nov; 10(11):1009-11. PubMed ID: 15522005
[TBL] [Abstract][Full Text] [Related]
20. Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections.
Cottreau J; Baker SF; DuPont HL; Garey KW
Expert Rev Anti Infect Ther; 2010 Jul; 8(7):747-60. PubMed ID: 20586560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]